The overall goal is to discover mechanisms of immune evasion and reveal biomarkers for precision medicine in ovarian cancer. Every year 500 women are diagnosed, and 300 women die from ovarian cancer in Finland. To develop more effective immune- and combination therapies to the most common high-grade serous ovarian cancer (HGSC), there is a critical need for a deeper understanding of the tumor-immune interactions. We aim to uncover the how the tumor cells evade the immune system using genomic profiling, single-cell spatial analysis, and artificial intelligence in an internationally unique dataset of over 500 HGSC patients. Using an innovative platform of immune-competent patient-derived organoids (iPDOs), or “mini-tumors”, we can capture the personalised responses to immune-and combination therapies. The proposed project will reveal the mechanisms of immune evasion and enable precision medicine in ovarian cancer.

2022

2026